| |
| |
|
| Insider
Information: |
Fridriksdottir Hafrun |
| Relationship: |
Executive VP, Global R&D |
| City: |
Parsippany |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
8,301 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,358,244 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
8,301 |
|
|
| Total
Value |
$1,358,244 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 4.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allergan plc |
AGN |
SVP, GLOBAL R&D |
2014-05-09 |
6,914 |
2013-10-01 |
0 |
Premium* |
|
|
Teva Pharmaceutical Industries L... |
TEVA |
Executive VP, Global R&D |
2022-05-17 |
1,387 |
2018-03-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGN |
Allergan plc |
SVP, GLOBAL R&D |
• – – |
2013-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,645 |
5,645 |
0 |
- |
|
| AGN |
Allergan plc |
SVP, GLOBAL R&D |
• – – |
2014-05-09 |
4 |
A |
$197.05 |
$250,056 |
D/D |
1,269 |
6,914 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,165 |
4,510 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,432 |
7,942 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-05 |
4 |
D |
$19.38 |
$30,136 |
D/D |
(1,555) |
6,387 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
7,399 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-03-19 |
4 |
S |
$17.88 |
$6,222 |
D/D |
(348) |
7,051 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-11-30 |
4 |
S |
$21.76 |
$20,304 |
D/D |
(933) |
8,829 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,711 |
9,762 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2018-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,640 |
13,469 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-01-02 |
4 |
AS |
$15.70 |
$25,799 |
D/D |
(1,643) |
11,826 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,353 |
17,179 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-02-14 |
4 |
AS |
$17.67 |
$32,529 |
D/D |
(1,841) |
15,338 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,165 |
16,503 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-04 |
4 |
AS |
$16.88 |
$6,905 |
D/D |
(409) |
16,094 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
17,106 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-03-18 |
4 |
AS |
$16.63 |
$5,919 |
D/D |
(356) |
16,750 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-11-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,133 |
24,883 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-12-02 |
4 |
AS |
$10.49 |
$45,214 |
D/D |
(4,310) |
20,573 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,640 |
25,213 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2019-12-31 |
4 |
AS |
$9.92 |
$24,396 |
D/D |
(2,459) |
22,754 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,120 |
38,874 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-10 |
4 |
AS |
$12.27 |
$68,025 |
D/D |
(5,544) |
33,330 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,203 |
56,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-14 |
4 |
AS |
$12.14 |
$139,295 |
D/D |
(11,472) |
45,061 |
0 |
% |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
